DNA vaccination with full-length or truncated Neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice
- 1 April 2000
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 7 (8) , 703-706
- https://doi.org/10.1038/sj.gt.3301151
Abstract
At the forefront of medicine, Gene Therapy brings you the latest research into genetic and cell-based technologies to treat disease. It also publishes Progress & Prospects reviews and News and Commentary articles, which highlight the cutting edge of the field.Keywords
This publication has 17 references indexed in Scilit:
- Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?Molecular Medicine Today, 1997
- Autoantibody to p185 erbB2/neu oncoprotein by vaccination with xenogenic DNACancer Immunology, Immunotherapy, 1997
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene.Molecular and Cellular Biology, 1987
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185Cell, 1986
- The neu oncogene encodes an epidermal growth factor receptor-related proteinNature, 1986
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985
- Amplification of a Novel v- erb B-Related Gene in a Human Mammary CarcinomaScience, 1985
- Cytotoxicity to tumor cells of monocytes from normal individuals and cancer patientsInternational Journal of Cancer, 1980